AnaptysBio, Inc. (ANAB)

AnaptysBio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	53.7	35.97	71.31	495.73	250.46	171.08
Short-Term Investments	300.97	354.94	369.93	52.37	143.2	203.21
Cash & Cash Equivalents	354.67	390.9	441.24	548.1	393.65	374.29
Cash Growth	-17.74%	-11.41%	-19.50%	39.23%	5.17%	-12.37%
Receivables	7.09	6.85	1.42	0.88	0	0
Other Current Assets	10.67	9.08	4.55	4.9	2.91	3.45
Total Current Assets	372.42	406.84	447.21	553.88	396.56	377.73
Property, Plant & Equipment	17.69	18.27	19.99	21.84	2.13	1.62
Long-Term Investments	15.47	27.03	142.94	67.1	17.61	54.31
Other Long-Term Assets	0.26	0.26	0.26	0.26	0.26	1.54
Total Long-Term Assets	33.42	45.55	163.18	89.19	19.99	57.46
Total Assets	405.84	452.39	610.38	643.07	416.55	435.2
Accounts Payable	4.58	4.7	2.78	1.74	4.22	16.24
Current Debt	1.81	1.78	1.64	1.51	0.34	1.38
Other Current Liabilities	25.9	30.97	21.63	12.85	15.26	11.92
Total Current Liabilities	32.3	37.44	26.05	16.1	19.82	29.54
Long-Term Debt	15.58	16.04	17.81	19.45	0	0
Other Long-Term Liabilities	310.18	310.81	304.41	251.09	0	0.65
Total Long-Term Liabilities	325.76	326.84	322.23	270.54	0	0.65
Total Liabilities	358.06	364.29	348.28	286.64	19.82	30.19
Total Debt	17.39	17.81	19.45	20.96	0.34	1.38
Debt Growth	-8.77%	-8.41%	-7.18%	6027.19%	-75.13%	-81.85%
Retained Earnings	-658.03	-614.1	-450.48	-321.75	-263.96	-244.03
Comprehensive Income	-0.62	-0.8	-5.25	-0.42	-0	0.34
Shareholders' Equity	47.78	88.1	262.1	356.43	396.73	405.01
Net Cash / Debt	337.28	373.09	421.79	527.14	393.31	372.91
Net Cash / Debt Growth	-18.15%	-11.55%	-19.99%	34.03%	5.47%	-11.12%
Net Cash Per Share	12.58	13.86	14.98	19.22	14.41	13.78
Working Capital	340.12	369.39	421.15	537.78	376.74	348.2
Book Value Per Share	1.78	3.27	9.31	12.99	14.53	14.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).